Latest News

  • OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
    EpiSwitch™ biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 EpiSwitch™ biomarkers have been shown to offer prognostic stratifications in lymphoma patients Data presented at the ASH Summit on Emerging Immunotherapies for Hematologic Diseases on 13 July 2018, in Washington DC
  • Turning A Phage
    Partnering with multiple institutions, UC San Diego launches North America’s first bacteriophage therapy center to use viruses as new weapon against multidrug-resistant bacteria; clinical trials planned
  • Steering Group calls for action in fighting influenza
    EU Manifesto on Influenza Vaccination launched detailing key strategies to improve influenza vaccination coverage rates in Europe
  • New project to transform biologics manufacture
    The Centre for Process Innovation (CPI), the UK’s technology innovation provider for process manufacturing, today announced that it is in the final stages of a BBSRC-funded collaboration project with the University of Edinburgh’s Roslin Institute, to transform the way in which valuable proteins are manufactured for research, veterinary and human health. The project, hosted at CPI’s state-of-the-art National Biologics Manufacturing Centre, aims to develop commercially viable and scalable methods to produce biologics in transgenic animals, which will enable the production of cost-efficient, highly pure, biologically active therapeutic proteins.
  • New report reveals UK has the strongest R&D pipeline in Europe and the UK sector is maturing
    ‘Pipeline Progressing: the UK’s global bioscience cluster in 2017’ launched by the BioIndustry Association and Informa Pharma Intelligence
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more